Abstract
While classical neuroleptics are characterized by dopamine D2 antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of these new atypical antipsychotics can be classified into three general groups: a) binding to D2 together with non-dopaminergic receptors, b) interaction with dopamine receptor subtypes other than D2 and c) selective binding to nondopaminergic systems, such as glutamatergic, sigma, neurotensin, and cannabinoid.
Keywords: Antipsychotic Drugs, D2 antagonism, dopamine receptor, neurotensin, glutamatergic, nondopaminergic
Mini-Reviews in Medicinal Chemistry
Title: Current Strategies for the Development of Novel Antipsychotic Drugs
Volume: 3 Issue: 3
Author(s): Jordi Bolos
Affiliation:
Keywords: Antipsychotic Drugs, D2 antagonism, dopamine receptor, neurotensin, glutamatergic, nondopaminergic
Abstract: While classical neuroleptics are characterized by dopamine D2 antagonism, this is also considered to be the cause of their neurological side effects. In recent years, novel antipsychotic drugs with improved efficacy, devoid of extrapyramidal effects are being developed. The mechanisms of action of these new atypical antipsychotics can be classified into three general groups: a) binding to D2 together with non-dopaminergic receptors, b) interaction with dopamine receptor subtypes other than D2 and c) selective binding to nondopaminergic systems, such as glutamatergic, sigma, neurotensin, and cannabinoid.
Export Options
About this article
Cite this article as:
Bolos Jordi, Current Strategies for the Development of Novel Antipsychotic Drugs, Mini-Reviews in Medicinal Chemistry 2003; 3 (3) . https://dx.doi.org/10.2174/1389557033488169
DOI https://dx.doi.org/10.2174/1389557033488169 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Membrane Pathology in Schizophrenia: Implication for Arachidonic Acid Signaling
Current Medicinal Chemistry - Central Nervous System Agents Potential Application of Induced Pluripotent Stem Cells in Cell Replacement Therapy for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets D2 Receptor Partial Agonists: Treatment of CNS Disorders of Dopamine Function
Current Topics in Medicinal Chemistry Effect of Polyherbal Drug Majun Falasfa on the Transgenic Drosophila Model of Parkinson’s Disease
Current Traditional Medicine Development of Tablet Device App for Parkinson’s Disease Patients’ Continuous Self-Monitoring and Management
Neuroscience and Biomedical Engineering (Discontinued) Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research Biophysics of Parkinsons Disease: Structure and Aggregation of α- Synuclein
Current Protein & Peptide Science Association between the Regulator of G-protein Signaling 9 Gene and Patients with Methamphetamine Use Disorder and Schizophrenia
Current Neuropharmacology A Review of Current Strategies for Treatment Resistant Obsessive-Compulsive Disorder
Current Drug Therapy The Effectiveness of Treatments for Cocaine Dependence in Schizophrenic Patients: A Systematic Review
Current Neuropharmacology Substance Abuse and Movement Disorders
Current Drug Abuse Reviews New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder
Current Psychopharmacology Structural Properties of the NMDA Receptor and the Design of Neuroprotective Therapies
Mini-Reviews in Medicinal Chemistry EDITORIAL [Hot Topic Recognition of Functional Roles of Free Radicals Guest Editor: István Bokkon]
Current Neuropharmacology Therapeutic Development of Interrelated Metabolic and Neurodegenerative Disorders
Current Pharmaceutical Design Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Discovery of MAO-B Inhibitors - Present Status and Future Directions Part I: Oxygen Heterocycles and Analogs
Mini-Reviews in Medicinal Chemistry On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Design and Synthesis of Dopaminergic Agonists
Current Medicinal Chemistry Editorial [Hot Topic: Novel Therapeutic Strategies in Neural Diseases Uncover Unexpected Disease Connections: From Neurodegeneration and Addiction to Pain and Depression (Guest Editor: Gonzalo Herradon)]
Current Pharmaceutical Design